Results 271 to 280 of about 769,897 (367)

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Magnetic guided stereotactic radioablation for mid-wall ventricular tachycardia: how to overcome limits of catheter ablation. [PDF]

Eur Heart J Case Rep
Magnocavallo M, Rossi P, Marchesano D, Bianchi S.   +3 more
europepmc   +1 more source

Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation.

, 1989
W Schützenberger, F Leisch, Klaus Kerschner, Wolfgang Harringer, W Herbinger   +4 more
openalex   +1 more source

Polymorphic Ventricular Tachycardia Detected by a Smartwatch in a Patient With Recurrent Syncope. [PDF]

JACC Case Rep
Avidan Y, Tabachnikov V, Danon A, Schliamser JE.   +3 more
europepmc   +1 more source

Ventricular tachycardia: Reply

The Journal of Thoracic and Cardiovascular Surgery, 1974
Ravindra Prabhu, Karen R. Lockert, Ruben L. Shapiro   +2 more
openaire   +3 more sources

Sodium‐glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: Systematic review and meta‐analysis

European Journal of Clinical Investigation, EarlyView.
Patients with transthyretin amyloid cardiomyopathy (ATTR‐CM) were excluded from randomized clinical trials (RCTs) evaluating sodium‐glucose cotransporter 2 inhibitors (SGLT2i); as a result, the effects of these agents on this population remain underexplored.
Paschalis Karakasis, Panagiotis Theofilis, Dimitrios Patoulias, Art Schuermans, Panayotis K Vlachakis, Aleksandra Klisic, Manfredi Rizzo, Nikolaos Fragakis   +7 more
wiley   +1 more source

Ketamine Terminating Persistent Ventricular Tachycardia. [PDF]

JACC Case Rep
Fahhoum R, Abaid B, Ellis Z, Lynch AJ, Nichols A.   +4 more
europepmc   +1 more source

Ventricular tachycardia: Focal pulsed field electroporation as a rescue therapy. [PDF]

Heart Rhythm O2
Santos RR, Paiva MS, Amador R, Matos D, Carmo P, Adragão P.   +5 more
europepmc   +1 more source

Electrocardiographic localization of the site of origin of ventricular tachycardia in patients with prior myocardial infarction

, 1989
Dennis L. Kuchar, Jeremy N. Ruskin, Hasan Garan   +2 more
openalex   +1 more source

CLLAF SCORE—A New Risk Score for Predicting Atrial Fibrillation in Treatment‐Naive CLL Patients Initiating First‐ and Second‐Generation BTK Inhibitor Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Background One of the limiting toxicities of BTKi is the development of atrial fibrillation (AF), with an incidence of 3%–16%. Aim This study aimed to identify patients with chronic lymphocytic leukemia (CLL) starting both first‐ and second‐generation BTKis who are at high risk of developing AF using a machine learning approach.
Tamar Tadmor, Guy Melamed, Hilel Alapi, Lior Rokach   +3 more
wiley   +1 more source